Legend Biotech 

Yahoo Finance • 3 months ago

Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients

Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients On Tuesday, Johnson & Johnson (NYSE:JNJ) announced results from a prespecified second interim analysis of Phase 3 CARTITUDE-4 study e... Full story

Yahoo Finance • 7 months ago

Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy

CARVYKTI® is the first CAR-T therapy for patients with relapsed and refractory multiple myeloma to receive a positive CHMP opinion for second line treatment SOMERSET, N.J., February 23, 2024--(BUSINESS WIRE)--Legend Biotech Corporation (N... Full story

Yahoo Finance • 7 months ago

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results

SOMERSET, N.J., February 13, 2024--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening disease... Full story

Yahoo Finance • 9 months ago

Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3

SOMERSET, N.J., January 03, 2024--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases... Full story

Yahoo Finance • 9 months ago

13 High Growth Healthcare Stocks to Buy

In this article, we will take a look at 13 high growth healthcare stocks to buy. To skip our analysis of the recent market activity, you can go directly to see the 5 Best High Growth Healthcare Stocks to Buy. For the purpose of this artic... Full story

Yahoo Finance • 10 months ago

Matthews Emerging Markets Small Companies Fund Adjusts Portfolio, Ecopro BM Sees Major Cut

Insight into the Latest 13F Filing Reveals Significant Portfolio Changes Matthews Emerging Markets Small Companies Fund (Trades, Portfolio), known for its strategic investments in Asia's burgeoning small-cap market, has revealed its 13F h... Full story

Yahoo Finance • 10 months ago

Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights

Legend Biotech Corporation (the "Company" or Legend Biotech), through its wholly owned subsidiary, Legend Biotech Ireland Limited, entered into an exclusive, global license agreement with Novartis Pharma AG. The Company granted Novartis th... Full story

Yahoo Finance • 10 months ago

Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3

The deal with Novartis seeks to advance Legend Biotech’s autologous CAR-T cell therapy candidate, LB2102, and other potential CAR-T cell therapies targeting Delta-like ligand protein 3 (DLL3), using the Novartis next-generation T-Charge™ C... Full story

Yahoo Finance • 11 months ago

Should You Hold Legend Biotech Corporation (LEGN)?

Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here. The fund declined 6.05% (Institutional Shares) in the quarter compared to a... Full story

Yahoo Finance • last year

This Top-Performing Small-Cap Manager Is Betting Big on China

The Matthews Emerging Markets Small Companies fund has delivered a 15.1% annualized three-year return, landing it in the top 1% of its peers. Here’s what manager Vivek Tanneeru is buying now.... Full story

Yahoo Finance • 2 years ago

Analysts Say These 3 Stocks Are Their Top Picks for the Rest of 2022

Farewell, July, it’s been a pleasure. Sentiment might finally be turning on Wall Street after the stock market recorded its best month since November 2020, buoyed by the tech giants better-than-expected quarterly results and the prospect o... Full story

Yahoo Finance • 2 years ago

2 Biotechs With Recent FDA Approvals to Hold for the Next Decade

With trials aimed at increasing addressable markets in the coming years, Legend and Immunocore could reward investors.... Full story

Yahoo Finance • 2 years ago

UPDATE 2-European drug regulator clears J&J, Legend's CAR-T therapy

(Adds background on Legend, CAR-T therapies) March 25 (Reuters) - The European Medicines Agency on Friday recommended the use of Johnson & Johnson and its partner Legend Biotech Corp's CAR-T therapy to treat multiple myeloma, nearly a mon... Full story